ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2424

Defining a Minimal Clinically Meaningful Difference (MCMD) in Estimated Glomerular Filtration Rate (eGFR) for Kidney Transplantation

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Mayne, Tracy J., Angion Biomedica, San Francisco, California, United States
  • Mohan, Sumit, Columbia University, New York, New York, United States
  • Schold, Jesse D., Cleveland Clinic, Cleveland, Ohio, United States
  • Weir, Matthew R., University of Maryland School of Medicine, Baltimore, Maryland, United States
  • Nordyke, Bob, Angion Biomedica, San Francisco, California, United States
Background

eGFR is an established measure of renal function & predicts clinical outcomes. A MCMD for eGFR has never been clearly defined.

Methods

Data source: United Network for Organ Sharing (OPTN) database
Study population: Adults (>18 years of age); received deceased donor kidney 01/01/2013 to 12/31/2018; multi-organ & non-incident transplants were excluded.
Analysis: Cox proportional hazards regression
Primary outcome: Death-censored graft survival starting 12-months post-transplantation.
Predictors: Recipient (gender, age, race, diabetes, body mass index, panel reactive antibodies); Donor (age, diabetes, hypertension, proteinuria); Transplantation (cold ischemia time, pump, DR locus mismatch, delayed graft function); 12-month eGFR (CKD-EPI).
Analysis. eGFR was stratified by bands of 5, 7 or 10 mL/min/1.73m2. Regressions compared each band to the next sequential band. A weighted mean hazard ratio was calculated using OPTN population eGFR distribution.

Results

The relationship between 12-month eGFR & graft failure is non-linear: HR=~3 to 4 at eGFR <15 mL/min/1.73m2; HR=~1.1 at eGFRs > 55. Mean HR=1.47 for 10 mL/min/1.73m2 bands; 1.30 at 7 mL; 1.19 at 5 mL.

Conclusion

Controlling for multiple factors, 12-month eGFR is a strong predictor of death-censored graft survival. Mean HR (1.19) is consistent with an effect size considered significant, clinically meaningful, & supporting of regulatory approval (eg, angiotensin receptor blockers; statins). This supports 5 mL/min/1.73m2 as the eGFR MCMD in kidney transplantation.

DISCLAIMER. The interpretation & reporting of these data are the responsibility of the authors & in no way should be seen as an official policy of or interpretation by the OPTN or the US Government.